4503 — Astellas Pharma Balance Sheet
0.000.00%
HealthcareConservativeLarge CapHigh Flyer
- ¥4tn
- ¥4tn
- ¥2tn
- 98
- 28
- 83
- 83
Annual balance sheet for Astellas Pharma, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2019 March 31st | C2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 311,074 | 324,943 | 326,128 | 318,267 | 396,624 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 365,348 | 373,505 | 362,722 | 423,018 | 445,778 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 857,159 | 867,514 | 872,588 | 923,354 | 1,049,954 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 173,483 | 268,600 | 264,623 | 269,044 | 286,459 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 1,897,648 | 2,315,169 | 2,273,628 | 2,332,395 | 2,456,518 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 497,665 | 798,708 | 592,372 | 687,411 | 726,034 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 639,252 | 1,026,001 | 887,513 | 872,087 | 948,564 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 1,258,396 | 1,289,168 | 1,386,115 | 1,460,308 | 1,507,954 |
Total Liabilities & Shareholders' Equity | 1,897,648 | 2,315,169 | 2,273,628 | 2,332,395 | 2,456,518 |
Total Common Shares Outstanding |